Substituted 6-azabenzimidazole compounds

US12258346B2 · kind B2 · utility

Assignee

• Gilead Sciences, Inc. · US

Inventors

• Gayatri Balan · Bellevue, US
• Mark J. Bartlett · Castro Valley, US
• Jayaraman Chandrasekhar · Redmond, US
• Julian A. Codelli · Mountlake Terrace, US
• John H. Conway · Seattle, US
• Jennifer L. Cosman Ellis · Foster City, US
• Rao V. Kalla · Cupertino, US
• Zachary A. Kasun · Seattle, US
• Musong Kim · Bellevue, US
• Seung H. Lee · Sammamish, US
• Jennifer R. Lo · Plainsboro, US
• Jennifer A. Loyer-Drew · Seattle, US
• Scott A. Mitchell · East Haven, US
• Thao Perry · San Jose, US
• Gary Phillips · Issaquah, US
• Patrick J. Salvo · Burien, US
• Sundaramoorthi Swaminathan · Burlingame, US
• Joshua J. Van Veldhuizen · Seattle, US
• Suet C. Yeung · Redmond, US
• Jeff Zablocki · Mountain View, US

Key dates

• Filing date: Dec 18, 2023
• Grant date: Mar 25, 2025
• Expiry date: Dec 18, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.